Abstract
Escherichia coli ST131 is a pandemic clone with high antibiotic resistance, and it is a major causative agent of urinary tract infection (UTI) and bloodstream infections. This study evaluated the distribution and expression of virulence genes and genotyping of E. coli O25b/ST131 by Multi-locus variable number tandem repeat analysis (MLVA) method among UTI in patients at Tehran hospitals, Iran.
A total of 107 E. coli isolates were collected from UTI patients. Polymerase chain reaction (PCR) amplification of the pabB gene was used to identify E. coli O25b/ST131 and the prevalence of sat and hlyA virulence genes was also analyzed. The microtiter method quantified biofilm formation ability in E. coli O25b/ST131. The Real-Time PCR (qRT-PCR) was performed to evaluate the expression of sat and hlyA genes. Finally, MLVA was performed for E. coli O25b/ST131 genotyping by targeting seven tandem repeats. SPSS-16 software was used for statistical analysis. Molecular study showed that 71% of isolates carried the pabB gene and were considered E. coli O25b/ST131 strains. Also, 45.8% and 17.8% of isolates carried sat and hlyA genes, respectively. The 57.9% isolates had biofilm formation ability. Expression of the studied virulence genes showed an increase in strong biofilm producing E. coli O25b/ST131 strains. A total of 76 (100%) E. coli O25b/ST131 strains were typed by the MLVA method.
High prevalence of E. coli O25b/ST131 isolates in UTI patients can be a serious warning to the treatment due to the high antibiotic resistance rate, expression of virulence genes, and biofilm formation.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Mohebi S, Hossieni Nave H, Norouzi A, Kandehkar Gharaman M, Taati Moghadam M. Detection of extended spectrum beta lactamases on class I integron in escherichia coli isolated from clinical samples. J Mazandaran Univ Med Sci 2016; 26(138): 66–76.
-
2.
Jamali S, Tavakoly T, Mojtahedi A, Shenagari M. The phylogenetic relatedness of blaNDM-1 harboring extended-spectrum β-lactamase producing uropathogenic Escherichia coli and Klebsiella pneumoniae in the North of Iran. Infect Drug Resist 2020;13: 651–7.
-
3.
Haghighatpanah M, Mojtahedi A. Characterization of antibiotic resistance and virulence factors of Escherichia coli strains isolated from Iranian inpatients with urinary tract infections. Infect Drug Resist 2019; 12: 2747–54.
-
4.
Bergeron CR, Prussing C, Boerlin P, Daignault D, Dutil L, Reid-Smith RJ, et al. Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada. Emerg Infect Dis 2012; 18(3): 415–21.
-
5.
Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global extraintestinal pathogenic Escherichia coli (ExPEC) lineages. Clin Microbiol Rev 2019; 32(3): e00135–18.
-
6.
Sadeghi M, Ebrahim-Saraie HS, Mojtahedi A, Nikokar I, Roushan ZA. Genetic diversity and prevalence of aminoglycoside modifying enzymes among Escherichia coli strains isolated from inpatients with urinary tract infections. Gene Rep 2020; 21: 100957.
-
7.
Platell JL, Johnson JR, Cobbold RN, Trott DJ. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods. Vet Microbiol 2011; 153(1–2): 99–108.
-
8.
Alqasim A, Abu Jaffal A, Alyousef AA. Prevalence and molecular characteristics of sequence type 131 clone among clinical uropathogenic Escherichia coli isolates in Riyadh, Saudi Arabia. Saudi J Biol Sci 2020; 27(1): 296–302.
-
9.
Moghadam MT, Mirzaei M, Moghaddam MFT, Babakhani S, Yeganeh O, Asgharzadeh S, et al. The challenge of global emergence of novel colistin-resistant Escherichia coli ST131. Microb Drug Resist 2021; 27: 1513–24.
-
10.
Roy PK, Ha AJ-W, Mizan MFR, Hossain MI, Ashrafudoulla M, Toushik SH, et al. Effects of environmental conditions (temperature, pH, and glucose) on biofilm formation of Salmonella enterica serotype Kentucky and virulence gene expression. Poult Sci 2021; 100(7): 101209.
-
11.
Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27(3): 543–74.
-
12.
Mandomando I, Vubil D, Boisen N, Quintó L, Ruiz J, Sigaúque B, et al. Escherichia coli ST131 clones harbouring AggR and AAF/V fimbriae causing bacteremia in Mozambican children: emergence of new variant of fimH27 subclone. Plos Negl Trop Dis 2020; 14(5): e0008274.
-
13.
Cha MK, Kang C-I, Kim SH, Cho SY, Ha YE, Wi YM, et al. Comparison of the microbiological characteristics and virulence factors of ST131 and non-ST131 clones among extended-spectrum β-lactamase–producing Escherichia coli causing bacteremia. Diagn Microbiol Infect Dis 2016; 84(2): 102–4.
-
14.
Li W, Raoult D, Fournier P-E. Bacterial strain typing in the genomic era. FEMS Microbiol Rev 2009; 33(5): 892–916.
-
15.
Moghadam M, Shariati A, Mirkalantari S, Karmostaji A. The complex genetic region conferring transferable antibiotic resistance in multidrug-resistant and extremely drug-resistant Klebsiella pneumoniae clinical isolates. New Microbes New Infections 2020; 36: 100693.
-
16.
Hadizadeh M, Norouzi A, Taghadosi R, Mohebi S, Mohammadi M, Hasanzade A, et al. Prevalence of qnr, intI, and intII genes in extendedspectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from clinical samples in Iran. Trop J Pharm Res 2017; 16(1): 141–7.
-
17.
Yousefi S, Mojtahedi A, Shenagari M. A survey of gyrA target-site mutation and qnr genes among clinical isolates of Escherichia coli in the north of Iran. Jundishapur J Microbiol 2018; 11(9).
-
18.
Moghadam MT, Nave HH, Mohebi S, Norouzi A. The evaluation of connection between integrons class I and II and ESBL-producing and Non-ESBL Klebsiella pneumoniae isolated from clinical samples, Kerman. Iran J Med Microbiol 2016; 10: 1–9.
-
19.
Kangachar SA, Mojtahedi A. Evaluation of integrons classes 1–3 in extended spectrum beta-lactamases and multi drug resistant Escherichia coli isolates in the North of Iran. Gene Rep 2018; 12: 299–303.
-
20.
Shahbazi S, Asadi Karam MR, Habibi M, Talebi A, Bouzari S. Distribution of extended-spectrum β-lactam, quinolone and carbapenem resistance genes, and genetic diversity among uropathogenic Escherichia coli isolates in Tehran, Iran. J Glob Antimicrob Resist 2018; 14: 118–25.
-
21.
Al-Kafaween M, Khan R, Bakar M, Tengku M. Characterization of biofilm formation by Escherichia coli: an in vitro study. J Appl Biol Biotechnol 2019; 7.
-
22.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25(4): 402–8.
-
23.
Caméléna F, Birgy A, Smail Y, Courroux C, Mariani-Kurkdjian P, Le Hello S, et al. Rapid and simple universal Escherichia coli genotyping method based on multiple-locus variable-number tandem-repeat analysis using single-tube multiplex PCR and standard gel electrophoresis. Appl Environ Microbiol 2019; 85(6): e02812–18.
-
24.
Shenagari M, Bakhtiari M, Mojtahedi A, Roushan ZA. High frequency of mutations in gyrA gene associated with quinolones resistance in uropathogenic Escherichia coli isolates from the north of Iran. Iran J Basic Med Sci 2018; 21(12): 1226.
-
25.
Mojtahedi A. The presence of extended-spectrum β-lactamase as a risk factor for MDR in clinical isolation of Escherichia coli. Trop Biomed 2017; 34(1): 98–109.
-
26.
Dadi BR, Abebe T, Zhang L, Mihret A, Abebe W, Amogne W. Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia. BMC Infect Dis 2020; 20(1): 108.
-
27.
Al-Jamei SA, Albsoul AY, Bakri FG, Al-Bakri AG. Extended-spectrum β-lactamase producing E. coli in urinary tract infections: a two-center, cross-sectional study of prevalence, genotypes and risk factors in Amman, Jordan. J Infect Public Health 2019; 12(1): 21–5.
-
28.
Minardi D, d'Anzeo G, Cantoro D, Conti A, Muzzonigro G. Urinary tract infections in women: etiology and treatment options. Int J Gen Med 2011; 4: 333–43.
-
29.
Moore KN, Day RA, Albers M. Pathogenesis of urinary tract infections: a review. J Clin Nurs 2002; 11(5): 568–74.
-
30.
Demirci-Duarte S, Unalan-Altintop T, Eser OK, Cakar A, Altun B, Sancak B, et al. Prevalence of O25b-ST131 clone and fosfomycin resistance in urinary Escherichia coli isolates and their relation to CTX-M determinant. Diagn Microbiol Infect Dis 2020; 98(1): 115098.
-
31.
Can F, Kurt-Azap Ö, İspir P, Nurtop E, Seref C, Loçlar İ, et al. The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli. J Glob Antimicrob Resist 2016; 4: 49–52.
-
32.
Hojabri Z, Mirmohammadkhani M, Darabi N, Arab M, Pajand O. Characterization of antibiotic-susceptibility patterns and virulence genes of five major sequence types of Escherichia coli isolates cultured from extraintestinal specimens: a 1-year surveillance study from Iran. Infect Drug Resist 2019; 12: 93–903.
-
33.
Coelho A, Mora A, Mamani R, López C, González-López JJ, Larrosa MN, et al. Spread of Escherichia coli O25b:H4-B2-ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). J Antimicrob Chemother 2010; 66(3): 517–26.
-
34.
Hojabri Z, Darabi N, Arab M, Saffari F, Pajand O. Clonal diversity, virulence genes content and subclone status of Escherichia coli sequence type 131: comparative analysis of E. coli ST131 and non-ST131 isolates from Iran. BMC Microbiol 2019; 19(1): 117.
-
35.
Kudinha T, Johnson JR, Andrew SD, Kong F, Anderson P, Gilbert GL. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol 2013; 51(10): 3270–6.
-
36.
Zhang S, Zhang Q, Huang J, Cao Y, Zhao Z, Li B. Epidemic potential of Escherichia coli O16:H41-ST131: compared with pandemic O25b:H30-ST131 lineage. Infect Drug Resist 2021; 14: 2625–32.
-
37.
Sarkar S, Vagenas D, Schembri MA, Totsika M. Biofilm formation by multidrug resistant Escherichia coli ST131 is dependent on type 1 fimbriae and assay conditions. Pathog Dis 2016; 74(3).
-
38.
Safadi RA, Abu-Ali GS, Sloup RE, Rudrik JT, Waters CM, Eaton KA, et al. Correlation between in Vivo biofilm formation and virulence gene expression in Escherichia coli O104:H4. Plos One 2012; 7(7): e41628.
-
39.
Nielsen JB, Albayati A, Jørgensen RL, Hansen KH, Lundgren B, Schønning K. An abbreviated MLVA identifies Escherichia coli ST131 as the major extended-spectrum β-lactamase-producing lineage in the Copenhagen area. Eur J Clin Microbiol Infect Dis 2013; 32(3): 431–6.
-
40.
Naseer U, Olsson-Liljequist BE, Woodford N, Dhanji H, Cantón R, Sundsfjord A, et al. Multi-locus variable number of tandem repeat analysis for rapid and accurate typing of virulent multidrug resistant Escherichia coli clones. Plos One 2012; 7(7): e41232.
-
41.
Lindstedt B-A, Brandal LT, Aas L, Vardund T, Kapperud G. Study of polymorphic variable-number of tandem repeats loci in the ECOR collection and in a set of pathogenic Escherichia coli and Shigella isolates for use in a genotyping assay. J Microbiol Methods 2007; 69(1): 197–205.
-
42.
Dolatyar Dehkharghani A, Haghighat S, Rahnamaye Farzami M, Rahbar M, Douraghi M. Clonal relationship and resistance profiles among ESBL-producing Escherichia coli 2021; 11(499).
-
43.
Samarasinghe S, Reid R, Al-Bayati M. The anti-virulence effect of cranberry active compound proanthocyanins (PACs) on expression of genes in the third-generation cephalosporin-resistant Escherichia coli CTX-M-15 associated with urinary tract infection. Antimicrob Resist Infect Control 2019; 8(1): 181.
-
44.
Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64(2): 274–7.
Please, download the file from HERE
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2021 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
696 |
| Journal Impact Factor | 2,298 |
| Rank by Impact Factor | Immunology 141/161 Microbiology 118/136 |
| Impact Factor without Journal Self Cites |
2,143 |
| 5 Year Impact Factor |
1,925 |
| Journal Citation Indicator | 0,39 |
| Rank by Journal Citation Indicator | Immunology 146/177 Microbiology 129/157 |
| Scimago | |
| Scimago H-index |
29 |
| Scimago Journal Rank |
0,362 |
| Scimago Quartile Score | Immunology and Microbiology (miscellaneous) (Q3) Medicine (miscellaneous) (Q3) |
| Scopus | |
| Scopus Cite Score |
3,6 |
| Scopus CIte Score Rank |
General Immunology and Microbiology 26/56 (Q2) Infectious Diseases 149/295 (Q3) Microbiology (medical) 66/118 (Q3) |
| Scopus SNIP |
0,598 |
| 2020 | |
| Total Cites | 662 |
| WoS | |
| Journal Impact Factor |
2,048 |
| Rank by | Immunology 145/162(Q4) |
| Impact Factor | Microbiology 118/137 (Q4) |
| Impact Factor | 1,904 |
| without | |
| Journal Self Cites | |
| 5 Year | 0,671 |
| Impact Factor | |
| Journal | 0,38 |
| Citation Indicator | |
| Rank by Journal | Immunology 146/174 (Q4) |
| Citation Indicator | Microbiology 120/142 (Q4) |
| Citable | 42 |
| Items | |
| Total | 40 |
| Articles | |
| Total | 2 |
| Reviews | |
| Scimago | 28 |
| H-index | |
| Scimago | 0,439 |
| Journal Rank | |
| Scimago | Immunology and Microbiology (miscellaneous) Q4 |
| Quartile Score | Medicine (miscellaneous) Q3 |
| Scopus | 438/167=2,6 |
| Scite Score | |
| Scopus | General Immunology and Microbiology 31/45 (Q3) |
| Scite Score Rank | |
| Scopus | 0,760 |
| SNIP | |
| Days from | 225 |
| submission | |
| to acceptance | |
| Days from | 118 |
| acceptance | |
| to publication | |
| Acceptance | 19% |
| Rate |
| 2019 | |
|---|---|
| Total Cites WoS |
485 |
| Impact Factor | 1,086 |
| Impact Factor without Journal Self Cites |
0,864 |
| 5 Year Impact Factor |
1,233 |
| Immediacy Index |
0,286 |
| Citable Items |
42 |
| Total Articles |
40 |
| Total Reviews |
2 |
| Cited Half-Life |
5,8 |
| Citing Half-Life |
7,7 |
| Eigenfactor Score |
0,00059 |
| Article Influence Score |
0,246 |
| % Articles in Citable Items |
95,24 |
| Normalized Eigenfactor |
0,07317 |
| Average IF Percentile |
7,690 |
| Scimago H-index |
27 |
| Scimago Journal Rank |
0,352 |
| Scopus Scite Score |
320/161=2 |
| Scopus Scite Score Rank |
General Immunology and Microbiology 35/45 (Q4) |
| Scopus SNIP |
0,492 |
| Acceptance Rate |
16% |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Online only Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2023 | Online subsscription: 680 EUR / 832 USD Print + online subscription: 760 EUR / 930 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Dec 2022 | 51 | 3 | 7 |
| Jan 2023 | 58 | 0 | 0 |
| Feb 2023 | 29 | 0 | 1 |
| Mar 2023 | 63 | 3 | 3 |
| Apr 2023 | 50 | 5 | 5 |
| May 2023 | 51 | 0 | 0 |
| Jun 2023 | 10 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory